Medpace's (MEDP) "Buy (B-)" Rating Reaffirmed at Weiss Ratings

Key Points

• Medpace's stock has received a "Buy (B-)" rating from Weiss Ratings, despite several other brokerages issuing mixed ratings ranging from "sell" to "hold."
• The company's latest earnings report showed an EPS of $3.10, exceeding analyst estimates, with year-over-year revenue growth of 14.2%.
• Insiders have sold a significant amount of stock recently, with reports indicating that over $74 million worth of shares were sold by company insiders in the last 90 days.

Medpace (NASDAQ:MEDP - Get Free Report)'s stock had its "buy (b-)" rating reiterated by Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

A number of other brokerages also recently issued reports on MEDP. UBS Group downgraded shares of Medpace from a "neutral" rating to a "sell" rating and lifted their price objective for the stock from $300.00 to $305.00 in a research report on Tuesday, July 29th. Rothschild Redb downgraded shares of Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, September 3rd. Jefferies Financial Group lifted their price objective on shares of Medpace from $400.00 to $450.00 and gave the stock a "hold" rating in a research report on Tuesday, September 9th. Barclays lifted their price objective on shares of Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. Finally, Zacks Research downgraded shares of Medpace from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 22nd. Three research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Medpace currently has an average rating of "Hold" and an average target price of $422.27.

Medpace Stock Performance

NASDAQ MEDP opened at $531.00 on Wednesday. The company has a market capitalization of $14.92 billion, a price-to-earnings ratio of 39.48, a price-to-earnings-growth ratio of 3.35 and a beta of 1.40. The company's 50-day simple moving average is $479.93 and its two-hundred day simple moving average is $372.01. Medpace has a one year low of $250.05 and a one year high of $547.15.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. The business had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company's revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Equities analysts expect that Medpace will post 12.29 earnings per share for the current fiscal year.

Insider Activity at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 3,000 shares of the business's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the sale, the general counsel owned 10,343 shares of the company's stock, valued at approximately $4,654,350. The trade was a 22.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Susan E. Burwig sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the sale, the vice president directly owned 57,500 shares in the company, valued at approximately $27,600,000. This represents a 14.81% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 161,266 shares of company stock worth $74,111,427 in the last 90 days. 20.30% of the stock is owned by insiders.

Institutional Trading of Medpace

Institutional investors and hedge funds have recently bought and sold shares of the business. Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after acquiring an additional 37 shares during the period. Brooklyn Investment Group lifted its stake in Medpace by 244.8% during the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after acquiring an additional 71 shares during the period. Whittier Trust Co. lifted its stake in Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after acquiring an additional 35 shares during the period. Employees Retirement System of Texas acquired a new stake in Medpace during the 2nd quarter valued at approximately $36,000. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Medpace during the 1st quarter valued at approximately $60,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.